Abstract
Tenofovir Disoproxil Fumarate (TDF) is antiretroviral medicine used treat AIDS as well as chronic Hepatitis-B. TDF is a prodrug of tenofovir and exists as dominant form due to lesser oral bioavailability of parent drug. TDF is now available in a fixed-dose combination with various antiretrovirals like Cobicistat, Efavirenz, Elvitegravir, Emtricitabine, Lamivudine, Rilpivirine, and Nevirapine. Hence, pharmaceutical analysis of TDF and applicability of different analytical methods have gained crucial importance. The present review article assesses the published analytical methods and a variety of approach for investigation of TDF in bulk drug as well as pharmaceutical formulations including combinations. This detailed review includes examination of around eighty analytical methods published during 2008 to 2016 using various techniques which include HPLC, HPTLC, and UV/Visible-Spectrophotometry. The review also illustrates the scope and limitations of many published analytical methods for analysis of TDF. Such detailed review will be of great help to the researcher who is working on TDF. Miscellaneous methods of rare but unique pharmaceutical distinction have also been given due consideration. The diagrammatic illustrations provide the statistical overview about the various methods referred for analysis of TDF.
Highlights
Tenofovir Disoproxil Fumarate (TDF) Fig. 1 is an antiretroviral medicine used to treat HIV/AIDS and chronic hepatitis B (Goicoechea et al, 2008)
TDF is mostly expelled with Glomerular filtration and in that being transported into renal proximal tubule cells through organic anion transporter-1 (OAT-1)
The present review offers a critical account on analytical methods published during 2008 to 2016 for determination of TDF
Summary
Vinod A Chaure[1], Saurabh B Ganorkar[1], Ganesh U Chaturbhuj[2], Sanjay J Surana[1] and Atul A Shirkhedkar[1]. C. Patel, Institute of Pharmaceutical Education and Research, Shirpur, Dist: Dhule (MS) India 425 405 2Institute of Chemical Technology, ICT, Matunga, Mumbai 400019. Received: July 11, 2018 Revised: Sep. 17, 2018 Accepted: Nov. 01, 2018 Published online: Nov 02, 2018
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Pharmaceutical Technology, Research and Management
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
